




Pat Quinn, Governor
LaMar Hasbrouck, MD, MPH, Director

422 South Fifth Street, Fourth Floor • Springfield, Illinois 62701-1824 • www.idph.state.il.us

MEMORANDUM

TO: LHD Administrators
RHCCs 

FROM: Winfred C. Rawls, Deputy Director
Office of Preparedness and Response

DATE: January 14, 2013

RE: **Emergency Medical Countermeasures Guidance
Use of 2009-10 H1N1 Influenza Pandemic SNS - Acquired Antivirals (Tamiflu and
Relenza) For Prophylaxis and Treatment 2012-13 Season Influenza**

This Guidance serves as an update to Guidance 2009-10 H1N1 SNS Medical Countermeasures EUA Termination Notice of June 23, 2010.

The Centers for Disease Control and Prevention (CDC) Office of Public Health Preparedness and Response (OPHPR) has advised that Tamiflu and Relenza formulations held in CDC's Strategic National Stockpile and those issued to States during the nationwide response to the 2009 H1N1 influenza pandemic were procured by the federal government specifically for use during an influenza pandemic. These products cannot be used for treatment of seasonal influenza, even under conditions of commercial shortages. Similar conditions exist for antiviral drugs purchased by States using the ASPR-subsidized purchase contract, which specifically restricts the use of the antiviral drugs to influenza pandemics only.

CDC continues to recommend influenza vaccination and antiviral treatment when appropriate. However, the early influenza season is straining the supply of Tamiflu liquid suspension for children in some parts of the United States. CDC is working with the U.S. Food and Drug Administration (FDA) to address the issue of localized shortages of Tamiflu liquid suspension in various locations around the country that are experiencing high influenza activity.

If an influenza pandemic is declared during a time when antiviral drugs are in short supply, the Strategic National Stockpile can rapidly distribute stockpiled antiviral drugs such as Tamiflu to protect the health of the American people.

FDA has posted information at <http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314742.htm#oseltamivir>. CDC's seasonal influenza updates are available at <http://www.cdc.gov/flu/weekly/summary.htm>.

If you have further questions, please contact Carla N. Little, Ph.D., eMCM/SNS Program Manager, 217-836-9367 or via email at carla.little@illinois.gov.

c: Office of Preparedness and Response Staff